Search results for "Vaccines"
Research on COVID-19 vaccines' duration, reactions, prioritization
Antibodies persisted six months after vaccination, and a graded dosing protocol allowed patients with reactions to a first shot to get a second. Surveyed Americans wanted to prioritize front-line workers and those with chronic conditions for vaccination, and a columnist finds reasons for hope.
https://immattersacp.org/weekly/archives/2021/04/13/1.htm
13 Apr 2021
Clot concerns with adenovirus COVID-19 vaccines, antibody treatment recommendations and data
Based on reports of cerebral venous sinus thrombosis with the Johnson & Johnson (Janssen) COVID-19 vaccine, federal officials recommended a pause in its use, which will be reconsidered on April 23. The NIH updated its recommendations on monoclonal antibody treatments for outpatients.
https://immattersacp.org/weekly/archives/2021/04/20/1.htm
20 Apr 2021
New COVID-19 boosters, DNA test for cancer risk OK’ed
This column reviews recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2023/11/new-covid-19-boosters-dna-test-for-cancer-risk-oked.htm
1 Nov 2023
MKSAP Quiz: Routine visit for a patient with chronic kidney disease
A 45-year-old man is evaluated during a routine visit in September. He has advanced chronic kidney disease due to IgA nephropathy. After his vaccination history is evaluated, what is the most appropriate additional vaccine to administer at this visit?
https://immattersacp.org/weekly/archives/2023/07/18/3.htm
18 Jul 2023
Expensive vaccines may wipe out wrong target—the doctor
New and expensive vaccines added to the schedule for adolescents, adults and children over the last several years have created a crisis in the delivery system that threatens to reduce or eliminate the private provider's role, say experts following the issue.
https://immattersacp.org/archives/2009/04/vaccine.htm
1 Apr 2009
Latest COVID-19 research on dexamethasone, hydroxychloroquine, a vaccine, tocilizumab
Peer-reviewed details on the recent trial of dexamethasone were released, and two new trials found no benefit to early treatment with hydroxychloroquine. Positive data from a phase 1 vaccine trial were also published, as was another study of tocilizumab.
https://immattersacp.org/weekly/archives/2020/07/21/1.htm
21 Jul 2020
Latest COVID-19 research details local vaccine reactions, ineffective outpatient treatments
A case series described delayed skin reactions to vaccination, and randomized trials indicated that ivermectin, azithromycin, and convalescent plasma didn't help mildly ill patients. Several studies focused on the increase in alcohol use during the pandemic.
https://immattersacp.org/weekly/archives/2021/03/09/1.htm
9 Mar 2021
More booster authorizations, research on vaccine safety and uptake
The FDA and CDC endorsed boosters of the Johnson & Johnson and Moderna vaccines. Recent research showed that COVID-19 vaccination was not associated with miscarriage, and a small financial incentive for receiving a COVID-19 vaccine or providing transportation to a vaccination site increased uptake.
https://immattersacp.org/weekly/archives/2021/10/26/1.htm
26 Oct 2021
New data on COVID-19 vaccines' effectiveness over time, boosters, barriers to uptake
Multiple recent studies assessed the effectiveness of the COVID-19 vaccines at different time intervals after vaccination, while others looked at the impact of booster shots. Results of a survey suggested that racial differences in vaccine uptake may be attributable to social barriers.
https://immattersacp.org/weekly/archives/2021/12/07/1.htm
7 Dec 2021
Latest COVID-19 research looks at vaccines' efficacy, thrombocytopenia risk
Thrombosis with thrombocytopenia is a risk with the Johnson & Johnson (Janssen) vaccine, but not those using mRNA technology, one study found, while other research quantified the vaccines' effectiveness over time. A trial found that monoclonal antibodies reduced progression from asymptomatic to symptomatic infection.
https://immattersacp.org/weekly/archives/2022/01/18/1.htm
18 Jan 2022